Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.58 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.50 |
| ▸ | FABP7 | O15540 | 2/20 | 0.50 |
| ▸ | CASP3 | P42574 | 2/20 | 0.48 |
| ▸ | MDM4 | O15151 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21332462 | 0.86 | KMT2A (0.66) | KMT2AEPHX2FABP5FABP7CASP3 | |
| SCHEMBL30238049 | 0.85 | KMT2A (0.64) | KMT2AEPHX2FABP5FABP7CASP3 | |
| SCHEMBL1800381 | 0.85 | KMT2A (0.64) | KMT2AEPHX2FABP5FABP7CASP3 | |
| SCHEMBL12370458 | 0.83 | EPHX2 (0.50) | KMT2AEPHX2FABP5FABP7CASP3 | |
| SCHEMBL401725 | 0.83 | KMT2A (0.67) | KMT2AEPHX2FABP5FABP7CASP3 | |
| SCHEMBL31031957 | 0.83 | KMT2A (0.67) | KMT2AEPHX2FABP5FABP7CASP3 | |
| SCHEMBL29367495 | 0.83 | KMT2A (0.67) | KMT2AEPHX2FABP5FABP7CASP3 | |
| SCHEMBL13688459 | 0.83 | KMT2A (0.62) | KMT2AEPHX2FABP5FABP7CASP3 | |
| SCHEMBL31173373 | 0.83 | KMT2A (0.62) | KMT2AEPHX2FABP5FABP7CASP3 | |
| SCHEMBL29728458 | 0.83 | KMT2A (0.62) | KMT2AEPHX2FABP5FABP7CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110039798-A1 | SUBSTITUTED NUCLEOSIDE DERIVATIVES WITH ANTIVIRAL AND ANTIMICROBIAL PROPERTIES | EASTERN VIRGINIA MEDICAL SCHOOL (US) | 2011-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039798-A1 | SUBSTITUTED NUCLEOSIDE DERIVATIVES WITH ANTIVIRAL AND ANTIMICROBIAL PROPERTIES | SAMHD1, TLR3, MAVS | KMT2A 3954/4885EPHX2 3962/4885FABP5 468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.